Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Abemaciclib + Pembrolizumab In Glioblastoma
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT04118036
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04092673
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center- Westchester, Harrison, New York, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6
- Conditions
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT04074785
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT04071262
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 27
- Registration Number
- NCT04049227
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
- Conditions
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 44
- Registration Number
- NCT04040205
- Locations
- 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4
- Registration Number
- NCT04031885
- Locations
- 🇺🇸
Yuma Regional Cancer Center, Yuma, Arizona, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Compassionate Cancer Care Medical Group Inc, Riverside, California, United States
A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT04003896
- Locations
- 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
- Conditions
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Nataliya Uboha
- Target Recruit Count
- 3
- Registration Number
- NCT03997448
- Locations
- 🇺🇸
Rutgers Cancer Institute of NewJjersey, New Brunswick, New Jersey, United States
🇺🇸Univerisy of Iowa Hospital and Clinics, Iowa City, Iowa, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 186
- Registration Number
- NCT03994796
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Breast, Grosse Pointe Woods, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.